Related Experiment Video
Updated: Feb 10, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year
Jifang Zhou1, Jin Han1,2,3, Edith A Nutescu1
1Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA.
Insights
Hydroxycarbamide (HC) use, especially optimal dosing and adherence, significantly lowers 30-day hospital readmissions for sickle cell disease (SCD) patients. This finding supports HC as a key treatment for reducing acute care utilization in SCD.
Area of Science:
- Hematology
- Pharmacology
- Public Health
Background:
- Sickle cell disease (SCD) is a genetic blood disorder leading to frequent hospitalizations.
- Evidence on hydroxycarbamide (HC, also known as hydroxyurea) reducing readmissions in SCD is limited.
- Acute care utilization represents a significant burden for SCD patients.
Purpose of the Study:
- To examine hydroxycarbamide (HC) utilization patterns in a large US population with SCD.
- To assess the association between HC use and acute care utilization, specifically 30-day readmission rates.
- To determine the impact of HC dosing and adherence on reducing hospital readmissions in SCD.
Main Methods:
- Analysis of a large, nationally-representative US health insurance claims database (2009-2014).
- Identification of 20,721 SCD-related inpatient and acute care encounters.
- Statistical analysis of HC exposure, dosage, adherence (proportion of days covered ≥0.80), and 30-day all-cause readmission rates.
Main Results:
- 21% of SCD-related admissions involved prior HC exposure.
- HC use was more prevalent in adolescents and young adults (10-29 years).
- Optimal HC dosing (≥0.5g/day) and high adherence (≥0.80) were associated with significantly lower 30-day all-cause readmission rates (ORs 0.72-0.59).
Conclusions:
- Optimal therapeutic dosing and high adherence to hydroxycarbamide (HC) are crucial for reducing 30-day hospital readmissions in patients with sickle cell disease (SCD).
- These findings highlight the importance of effective HC management in mitigating acute care needs for SCD patients.
Abstract:
Sickle cell disease (SCD) is a congenital haemoglobinopathy that causes frequent acute care/emergency room visits and hospital admissions for affected individuals. Evidence from population-based studies demonstrating the role of hydroxycarbamide (HC, also termed hydroxyurea) in reducing hospital readmission rates is limited. Our objective was to describe the use of HC and its association with acute care utilization and readmission rates using a large, nationally-representative US health insurance claims database over a 6-year period between 2009 and 2014. We identified 20 721 SCD-related inpatient and acute care encounters. Patients had been exposed to HC within 6 months prior to admission in 4263 (21%) of SCD-related admission events. HC use was more common among children aged 10-17 years and young adults aged 18-29 years. HC was associated with lower 30-day all-cause readmission rates in adults treated with average daily doses ≥1 g (odds ratio [OR], 0·72, 95% confidence interval [CI] 0·52-0·99) and doses of 0·5-1 g (OR, 0·73, 95% CI 0·57-0·93), compared to HC treatment with average daily doses of <0·5 g; adherence to HC with proportion of days covered of ≥0·80 was also associated with significantly lower 30-day all-cause readmission risks (OR, 0·59, 95% CI 0·41-0·84). Optimal therapeutic dosing and adherence to HC treatment significantly reduces 30-day readmissions among patients with SCD.
Related Concept Videos
Hospitals-II
Nurses that work in...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Hospitals-I
Cumulative Frequency Distribution
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

